Multiple Sclerosis
Conditions
Brief summary
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.
Detailed description
Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist. Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center. Repeat gait analysis will be performed after one year of treatment.
Interventions
DRUGGlatiramer acetate
Sponsors
Sheba Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of multiple sclerosis * EDSS less than 5.5 * No cognitive disability
Exclusion criteria
* EDSS over 5.5 * Inability to cooperate with gait analysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Computerized gait analysis: at the beginning of treatment and after 1 year | — |
Countries
Israel
Contacts
Primary ContactUri Givon, MD
Outcome results
None listed